Street View: India's ICICI Life faces regulatory risks after Q2 beat

ICICI Life Insurance

14/10/2026 06:41

** ICICI Life Insurance ICIR.NS earnings at risk from slower agent and bank business, weaker renewals and regulatory changes in the second half of financial year 2027, brokers say
** Firm's September quarter results were broadly positive, with strong premium sales and new-business profit growth led by protection and annuity products
        
GROWTH UPBEAT BUT REGULATIONS KEY
** Kotak Institutional Equities ("Buy"; PT: 700 rupees) says the quarter was solid, but distribution reforms, especially credit-life commission cuts, create uncertainty for growth and margins    
** Morgan Stanley ("Overweight"; price target: 670 rupees) says value of new business beat estimates on stronger margins and protection growth, though persistency remains a watch point
** Jefferies ("Buy"; PT: 670 rupees) says the margin miss and slow banca/agency growth are priced in, with valuations offering favourable risk-reward
** HSBC ("Buy"; PT: 582 rupees) says improving fundamentals and product mix support steady growth, while regulatory clarity and Prudential's stake sale are key catalysts



 (Reporting by Bharath Rajeswaran in Bengaluru)
 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))